Renal Insufficiency in Breast Cancer Patients: High Prevalence and Reduced Survival

• Published in: Cancer research (Chicago, Ill.) Ill.), 2009-12, Vol.69 (24_Supplement), p.2054-2054
• Main Authors: Launay-Vacher, V., Janus, N., Gligorov, J., Spano, J., Ray-Coquard, I., Oudard, S., Morere, J., Rey, J., Pourrat, X., Deray, G., Beuzeboc, P.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.SABCS-09-2054

BackgroundThe IRMA-1 study was the first to report on the high prevalence of renal insufficiency (RI) in 1898 breast cancer patients. The IRMA-2 study was started one year later, in another cohort of patients, and consisted of 2 phases: a cross-sectional study, similar to IRMA-1, and a 2-year retrospective follow-up of the patients to evaluate the impact of RI on survival. Data from the phase 1 of IRMA-2 were compared to the results of IRMA-1 in terms of RI prevalence and the potential association between RI and cancer survival was evaluated. We present here the results for IRMA-2 patients with breast cancer.Methods:The IRMA-1 and IRMA-2 studies included 4684 and 4945 patients, respectively, among which 1898 in IRMA-1 and 1816 in IRMA-2 had breast cancer (no dialysis). Sex, age, weight, serum creatinine (SCR), metastasis (bone and/or visceral), and anticancer drugs were collected. GFR was estimated with the aMDRD formula. RI was defined as aMDRD110µmol/l) was 2.0% (vs. 1.6% in IRMA-1), that of a GFR < 90 ml/min/1.73m² was 50.0% (vs. 50.8%) and that of a GFR < 60 ml/min/1.73m² was 7.7% (vs. 7.8%). No statistical different were found between the 2 populations.Among these 1816 patients, 1601 with available data (aMDRD and follow-up) were included in the survival analysis. RI at inclusion was strongly linked to mortality (Log Rank test, p